Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of ... MarketWatch (press release) Prior therapies included alkylating agents, stem cell transplant, thalidomide, lenalidomide and anthracyclines, and bortezomib in the bortezomib-treated patients. The primary endpoint was ORR and secondary endpoints included CBR, TTP, DOR, ... |
